AXSOME THERAPEUTICS ($AXSM) is expected to release its quarterly earnings data on Monday, August 4th before market open, per Finnhub. Analysts are expecting revenue of $141,740,638 and earnings of -$1.13 per share.
You can see Quiver Quantitative's $AXSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AXSOME THERAPEUTICS Insider Trading Activity
AXSOME THERAPEUTICS insiders have traded $AXSM stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 65,673 shares for an estimated $6,993,636.
- HUNTER R. MURDOCK (General Counsel) has made 0 purchases and 5 sales selling 36,014 shares for an estimated $3,647,496.
- NICK PIZZIE (Chief Financial Officer) has made 0 purchases and 2 sales selling 15,000 shares for an estimated $1,951,530.
- MARK COLEMAN has made 0 purchases and 3 sales selling 10,500 shares for an estimated $1,105,848.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AXSOME THERAPEUTICS Hedge Fund Activity
We have seen 188 institutional investors add shares of AXSOME THERAPEUTICS stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 1,128,636 shares (-27.9%) from their portfolio in Q1 2025, for an estimated $131,632,816
- RA CAPITAL MANAGEMENT, L.P. removed 1,000,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $116,630,000
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 653,807 shares (-44.5%) from their portfolio in Q1 2025, for an estimated $76,253,510
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 644,785 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $75,201,274
- D. E. SHAW & CO., INC. added 527,319 shares (+2591.8%) to their portfolio in Q1 2025, for an estimated $61,501,214
- LAZARD ASSET MANAGEMENT LLC removed 508,420 shares (-94.6%) from their portfolio in Q1 2025, for an estimated $59,297,024
- BOXER CAPITAL MANAGEMENT, LLC removed 470,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $54,816,100
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AXSOME THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AXSM in the last several months. We have seen 14 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/03/2025
- RBC Capital issued a "Outperform" rating on 06/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/10/2025
- Needham issued a "Buy" rating on 06/09/2025
- Oppenheimer issued a "Outperform" rating on 06/03/2025
- Wells Fargo issued a "Overweight" rating on 05/06/2025
- Baird issued a "Outperform" rating on 05/06/2025
To track analyst ratings and price targets for AXSOME THERAPEUTICS, check out Quiver Quantitative's $AXSM forecast page.
AXSOME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AXSM recently. We have seen 16 analysts offer price targets for $AXSM in the last 6 months, with a median target of $178.0.
Here are some recent targets:
- Sean Laaman from Morgan Stanley set a target price of $190.0 on 07/03/2025
- Leonid Timashev from RBC Capital set a target price of $186.0 on 06/12/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $180.0 on 06/10/2025
- Ami Fadia from Needham set a target price of $150.0 on 06/09/2025
- Matthew Hershenhorn from Oppenheimer set a target price of $185.0 on 06/03/2025
- Cerena Chen from Wells Fargo set a target price of $165.0 on 05/06/2025
- Joel Beatty from Baird set a target price of $162.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
